Chart Of The Day: Pfizer Bull-Bear Struggle Could Continue Till After Q4 Report

 | Feb 07, 2022 15:25

Pharmaceuticals giant Pfizer (NYSE:PFE), co-developer with BioNTech (NASDAQ:BNTX) of one of the most widely used COVID-19 vaccines in the developed world, is scheduled to release its Q4 2021 results on Tuesday, Feb. 8, before the opening bell.

Consensus estimates are forecasting EPS of $0.8742 on revenue of $24.16 billion. That's more than double the year-ago results for both metrics.

Analysts at Goldman Sachs remain neutral on the New York City-based pharma giant ahead of the company's 2022 guidance. They've set a 12-month price target of $57 for the stock, which closed Friday at $53. Goldman's forecast represents a 7.5% upside.

While expectations for earnings from other, newer drugs like Paxlovid, Pfizer's still-new anti-COVID pill which received emergency use authorization in the US at the end of December, are unclear, there is a consensus that the company is well-positioned to benefit from the ongoing need for its COVID-related vaccine.

Though PFE fundamentals look bullish, technical signals regarding supply and demand are less clear.